Whistleblower lawyers are no stranger to facing off against formidable defense teams.
But on Thursday afternoon, lawyers for a pair of qui tam plaintiffs in a long-running False Claims Act suit who claim that Gilead Sciences Inc. improperly received hundreds of millions of dollars in government reimbursements for adulterated HIV drugs will face off against an unusual opponent: Lawyers from the U.S. Department of Justice.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
